Metraipolis › archive › dc_cc4844b4fde4

Impact of CYP2C19 point-of-care testing on the clinical outcome in patients receiving personalized clopidogrel therapy: systemic review and meta-analysis — Europe PMC PMID:41357895

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41357895
DOI
10.3389/fphar.2025.1621327
License (as archived)
solo-consultazione
Archived
2026-11-08T09:06:13.096Z
SHA-256 of the archived text
0f9d669ddf9c590f3bd299a0032b2c8f7b581188730d2dbe8071fad3c361e49b
Stable URL of this page
https://metraipolis.com/documento/dc_cc4844b4fde4

How to cite

Impact of CYP2C19 point-of-care testing on the clinical outcome in patients receiving personalized clopidogrel therapy: systemic review and meta-analysis — Europe PMC PMID:41357895 — Europe PMC (en), https://europepmc.org/article/MED/41357895 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_cc4844b4fde4 (Metraipolis archive dc_cc4844b4fde4, sha256 0f9d669ddf9c590f3bd299a0032b2c8f7b581188730d2dbe8071fad3c361e49b)
BibTeX
@misc{dccc4844b4fde4,
  title = {Impact of CYP2C19 point-of-care testing on the clinical outcome in patients receiving personalized clopidogrel therapy: systemic review and meta-analysis — Europe PMC PMID:41357895},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41357895},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_cc4844b4fde4; sha256 0f9d669ddf9c590f3bd299a0032b2c8f7b581188730d2dbe8071fad3c361e49b},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41357895. Agents can read the archived copy with the MCP tool read_document.